ArticleCureus2025
Posterior Reversible Encephalopathy Syndrome Potentially Associated With Erythropoietin Analogs: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a potentially life-threatening but reversible neurological disorder. Commonly seen in the intensive care unit (ICU), PRES can arise from uncontrolled hypertension, renal failure, or the use of immunosuppressants and cytotoxic drugs. Erythropoietin (EPO) analogs help manage anemia in chronic kidney disease, but their hypertensive effects may lead to PRES. We report a patient with end-stage renal disease presenting with PRES that occurred four months after commencing darbepoetin alfa and closely correlated with darbepoetin use. Brain MRI confirmed the diagnosis. Discontinuing the drug and managing blood pressure (BP) resulted in complete neurological recovery. Re-challenging the patient upon recurrence strengthened the causal link. Therefore, we emphasize that healthcare providers should maintain a high index of suspicion for PRES related to EPO in patients in the ICU with hypertension who develop neurological symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.